WEBULL

Can Boston Scientific (BSX) Sustain Its Momentum As Minimally Invasive Care Becomes Mainstream?

Simply Wall St · 2d ago
  • Recently, Boston Scientific reported past-year revenue growth of 23% and said its earnings per share have roughly tripled over the last five years, reflecting broad demand for its minimally invasive devices across cardiovascular, neurology, and oncology treatments.
  • Because its portfolio aligns with aging populations, rising chronic disease, and demand for less invasive procedures, Boston Scientific is positioned to benefit from powerful long-term healthcare usage trends and international expansion.
  • Next, we’ll examine how Boston Scientific’s rapid revenue and earnings growth shapes its investment narrative and longer-term earnings assumptions.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Boston Scientific Investment Narrative Recap

To own Boston Scientific, you need to believe its minimally invasive devices can keep gaining share as procedures grow worldwide, while management manages costs and integration risks. The latest 23% revenue growth and tripling of EPS over five years reinforce the near term catalyst of accelerating adoption of therapies such as FARAPULSE and WATCHMAN, but do not materially change the biggest current risk, which remains margin pressure from tariffs and product lifecycle or regulatory setbacks.

The recent Q3 2025 earnings release, with sales rising to US$5,065 million and net income reaching US$755 million, is especially relevant here because it shows how strong demand is translating into higher profitability even as Boston Scientific absorbs tariff headwinds and impairment charges. For investors, that profitability trend is central to judging whether current growth in advanced therapies can offset upcoming cost pressures and competitive challenges.

But investors should also be aware that heavier tariffs and product discontinuations could start to...

Read the full narrative on Boston Scientific (it's free!)

Boston Scientific's narrative projects $25.4 billion revenue and $4.8 billion earnings by 2028.

Uncover how Boston Scientific's forecasts yield a $126.48 fair value, a 36% upside to its current price.

Exploring Other Perspectives

BSX 1-Year Stock Price Chart
BSX 1-Year Stock Price Chart

Seven fair value estimates from the Simply Wall St Community span roughly US$66.90 to US$126.48, underlining how far apart individual assessments can be. When you set those views against the current risk of tariff driven margin pressure, it becomes even more important to compare multiple opinions on Boston Scientific’s long term earnings power.

Explore 7 other fair value estimates on Boston Scientific - why the stock might be worth as much as 36% more than the current price!

Build Your Own Boston Scientific Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.